Publication | Closed Access

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

Advanced CancerOncologyHealth SciencesMedicineImmune Checkpoint InhibitorPharmacotherapyMulti-drug Resistance Protein-1Anti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyInhibitor SulindacCancer ResearchDrug DiscoveryDrug Resistance